Chia-Wei Hsu

Dr. Chia-Wei Hsu

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2012 in Journal of Proteome Research
Verified
Journal Article
Closed access
CCChien-Lun Chen
Chien-Lun Chen
YLYue-Fan Lai
Yue-Fan Lai
Petrus TangPetrus Tang
Petrus Tang
KCKun-Yi Chien
Kun-Yi Chien
JYJau-Song Yu
Jau-Song Yu
Yi-Ting ChenYi-Ting Chen
Yi-Ting Chen

1 June 2010 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
CWChih-Ching Wu
Chih-Ching Wu
CHChia-Wei Hsu
Chia-Wei Hsu
CCChi-De Chen
Chi-De Chen
CYChia-Jung Yu
Chia-Jung Yu
KCKai-Ping Chang
Kai-Ping Chang
JYJau-Song Yu
Jau-Song Yu
Although cancer cell secretome profiling is a promising strategy used to identify potential body fluid-accessible cancer biomarkers, questions remain regarding the depth to which the cancer cell secretome can be mined and the efficiency with which researchers can select useful candidates from the growing list of identified proteins. Therefore, we analyzed the secretomes of 23 human cancer cell lines derived from 11 cancer types using one-dimensional SDS-PAGE and nano-LC-MS/MS performed on an LTQ-Orbitrap mass spectrometer to generate a more comprehensive cancer cell secretome. A total of 31,180 proteins was detected, accounting for 4,584 non-redundant proteins, with an average of 1,300 proteins identified per cell line. Using protein secretion-predictive algorithms, 55.8% of the proteins appeared to be released or shed from cells. The identified proteins were selected as potential marker candidates according to three strategies: (i) proteins apparently secreted by one cancer type but not by others (cancer type-specific marker candidates), (ii) proteins released by most cancer cell lines (pan-cancer marker candidates), and (iii) proteins putatively linked to cancer-relevant pathways. We then examined protein expression profiles in the Human Protein Atlas to identify biomarker candidates that were simultaneously detected in the secretomes and highly expressed in cancer tissues. This analysis yielded 6–137 marker candidates selective for each tumor type and 94 potential pan-cancer markers. Among these, we selectively validated monocyte differentiation antigen CD14 (for liver cancer), stromal cell-derived factor 1 (for lung cancer), and cathepsin L1 and interferon-induced 17-kDa protein (for nasopharyngeal carcinoma) as potential serological cancer markers. In summary, the proteins identified from the secretomes of 23 cancer cell lines and the Human Protein Atlas represent a focused reservoir of potential cancer biomarkers.

31 August 2010 in Journal of Proteome Research
Verified
Journal Article
Closed access
Yi-Ting ChenYi-Ting Chen
Yi-Ting Chen
CCChien-Lun Chen
Chien-Lun Chen
HCHsiao-Wei Chen
Hsiao-Wei Chen
TCTing Chung
Ting Chung
CWChih-Ching Wu
Chih-Ching Wu
JYJau-Song Yu
Jau-Song Yu


6 September 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCTingwen Chen
Tingwen Chen
CLChi-Ching Lee
Chi-Ching Lee
HLHsuan Liu
Hsuan Liu
CWChi-Sheng Wu
Chi-Sheng Wu
CPCurtis Pickering
Curtis Pickering
YCYu-Sun Chang
Yu-Sun Chang
Oral squamous cell carcinoma is a prominent cancer worldwide, particularly in Taiwan. By integrating omics analyses in 50 matched samples, we uncover in Taiwanese patients a predominant mutation signature associated with cytidine deaminase APOBEC, which correlates with the upregulation of APOBEC3A expression in the APOBEC3 gene cluster at 22q13. APOBEC3A expression is significantly higher in tumors carrying APOBEC3B-deletion allele(s). High-level APOBEC3A expression is associated with better overall survival, especially among patients carrying APOBEC3B-deletion alleles, as examined in a second cohort (n = 188; p = 0.004). The frequency of APOBEC3B-deletion alleles is ~50% in 143 genotyped oral squamous cell carcinoma -Taiwan samples (27A3B−/−:89A3B+/−:27A3B+/+), compared to the 5.8% found in 314 OSCC-TCGA samples. We thus report a frequent APOBEC mutational profile, which relates to a APOBEC3B-deletion germline polymorphism in Taiwanese oral squamous cell carcinoma that impacts expression of APOBEC3A, and is shown to be of clinical prognostic relevance. Our finding might be recapitulated by genomic studies in other cancer types.

1 September 2019 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
HCHao-Wei Chu
Hao-Wei Chu
KCKai-Ping Chang
Kai-Ping Chang
CHChia-Wei Hsu
Chia-Wei Hsu
ICIan Yi-Feng Chang
Ian Yi-Feng Chang
HLHao-Ping Liu
Hao-Ping Liu
CWChih-Ching Wu
Chih-Ching Wu
Oral cavity squamous cell carcinoma (OSCC) is one of the most common cancers worldwide. In Taiwan, OSCC is the fifth leading cause of cancer-related mortality and leads to 2800 deaths per year. The poor outcome of OSCC patients is principally ascribed to the fact that this disease is often advanced at the time of diagnosis, suggesting that early detection of OSCC is urgently needed. Analysis of cancer-related body fluids is one promising approach to identify biomarker candidates of cancers. To identify OSCC biomarkers, salivary proteomes of OSCC patients, individuals with oral potentially malignant disorders (OPMDs), and healthy volunteers were comparatively profiled with isobaric tags for relative and absolute quantitation (iTRAQ)-based mass spectrometry (MS). The salivary levels of 67 and 18 proteins in the OSCC group are elevated and decreased compared with that in the noncancerous group (OPMD and healthy groups), respectively. The candidate biomarkers were further selected using the multiple reaction monitoring (MRM)-MS and validated with the immunoassays. More importantly, the higher salivary level of three proteins, complement factor H (CFH), fibrinogen alpha chain (FGA), and alpha-1-antitrypsin (SERPINA1) was correlated with advanced stages of OSCC. Our results indicate that analysis of salivary proteome is a feasible strategy for biomarker discovery, and the three proteins are potential salivary markers for OSCC diagnosis.